Skip to main navigation
×
CLOSE
Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb
®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
News
Publications
Careers
Corporate
Management
Partners
Contact
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
ActivMAb
®
Contact
Science in the service of medicine
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab Neurology
Pepinemab Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
Contact Us
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Shareholder Tools
Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter
Filter by content type
(-)
News
(150)
Filter by form group
Filter by year
2024
(5)
2023
(20)
2022
(15)
2021
(18)
2020
(17)
2019
(20)
2018
(11)
2017
(3)
2016
(6)
2015
(13)
2014
(7)
2013
(4)
2012
(3)
2011
(5)
2010
(3)
Search
News
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
News
Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery
News
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
News
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
News
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
News
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation
News
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
News
Vaccinex, Inc. awarded three Qualifying Therapeutic Discovery Project (QTDP) grants under the Patient Protection and Affordable Care Act of 2010 (PPACA)
News
Vaccinex To Present at the 4th Annual Therapeutic Monoclonal Antibody Discovery Conference
News
Vaccinex To Present at the 6th Annual PEGS Protein Engineering Summit
Pagination
Previous page
‹‹
Page 2
Next page
››